S1P1 agonist 7 是一种强效、具备口服活性的 β-抑制蛋白偏向型 S1P1 激动剂(EC50(G-protein) = 12.7 nM,EC50(β-arrestin) = 3.23 nM),具有强效的免疫调节活性和良好的安全性,具备优异的代谢稳定性、微弱至中度的 CYP 抑制能力以及不作用于 S1P3 受体的高选择性,在实验性自身免疫性脑脊髓炎小鼠模型中展现出良好的药代动力学特性,能够有效降低循环淋巴细胞数量并显著减轻疾病的严重程度,可用于多发性硬化症研究。
S1P1 agonist 7
产品编号: MS-B92893 分子式: C23H22N2O5 分子量: 406.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

S1P1 agonist 7 是一种强效、具备口服活性的 β-抑制蛋白偏向型 S1P1 激动剂(EC50(G-protein) = 12.7 nM,EC50(β-arrestin) = 3.23 nM),具有强效的免疫调节活性和良好的安全性,具备优异的代谢稳定性、微弱至中度的 CYP 抑制能力以及不作用于 S1P3 受体的高选择性,在实验性自身免疫性脑脊髓炎小鼠模型中展现出良好的药代动力学特性,能够有效降低循环淋巴细胞数量并显著减轻疾病的严重程度,可用于多发性硬化症研究。

生物实验数据

生物活性 S1P1 agonist 7 is a potent, orally active β-arrestin-biased S1P1 agonist (EC50(G-protein) = 12.7 nM, EC50(β-arrestin) = 3.23 nM) with potent immunomodulatory activity and a favorable safety profile, exhibiting excellent metabolic stability, weak-to-moderate CYP inhibition, and high selectivity with no activity at the S1P3 receptor, and it demonstrates favorable pharmacokinetic properties in the experimental autoimmune encephalomyelitis mouse model, effectively reduces circulating lymphocyte counts, and significantly attenuates disease severity, making it useful for multiple sclerosis research.
体外研究
(In Vitro)

S1P1 agonist 7 (compound 28) 的分子对接研究表明,其相对于 Fingolimod (MS-N91571) 表现出 4.51 倍的 β-抑制蛋白偏向性,其 G 蛋白信号通路 EC50 为 12.7 nM,β-抑制蛋白招募 EC50 为 3.23 nM。
S1P1 agonist 7 (1-10 µM,15-60 分钟) 在所有的人、大鼠和小鼠的肝微粒体中均表现出高度稳定性,且在 10 µM 浓度下对大多数 CYP 同工酶无显著抑制作用。
S1P1 agonist 7 (从 100 μM 起始浓度进行梯度稀释,90 分钟) 在 Chem-4/G15 和 CHO-K1 EDG1 细胞模型中显示出对 S1P1 受体的高选择性,其 G 蛋白信号通路的 EC50 值为 0.014 μM,β-抑制蛋白招募的 EC50 值为 0.0023 μM,且仅对 S1P5 受体表现出微弱活性。
S1P1 agonist 7 (0.041-10 μM,2 分钟) 即使在最高测试浓度下,也未在人类 iPSC 来源的心肌细胞中引起任何可观察到的峰值频率或搏动速率的变化。

体内研究
(In Vivo)

S1P1 agonist 7 (1、3 和 10 mg/kg,灌胃,单次给药) 可降低 C57BL/6N 小鼠的外周血淋巴细胞计数。
S1P1 agonist 7 (10 mg/kg,灌胃,每日一次,连续 23 天) 在 MOG35-55 (MS-R86214) 诱导的 EAE 小鼠模型中表现出强大的保护作用,能够减缓其疾病发作、抑制病情进展并减轻相关的病理损伤。

Animal Model: Female C57BL/6N mice (8 weeks old) immunized with MOG/CFA emulsion and received PTX on two consecutive days to induce EAE
Dosage: 10 mg/kg
Administration: i.g., daily for 23 days
Result: Delayed disease onset and reduced symptom severity, as indicated by lower cumulative and mean maximum clinical scores.
Maintained its prophylactic effect until the peak of disease severity, which occurred around 17 dpi.
Prevented body weight loss and lowered disease incidence in EAE mice, indicating a protective effect.
Moderated disease progression, and led to a steady reduction in symptom severity until 34 dpi, demonstrating a moderate therapeutic effect comparable to that of Siponimod (MS-T82875).
Significantly reduced the cumulative clinical score from 19 dpi (the peak of EAE) to 34 dpi.
Prevented body weight loss compared to the vehicle-treated group.
Markedly reduced demyelination in the spinal cord's dorsal column and ventral white matter.
Reduced immune cell infiltration and partially preserved myelin integrity.
Animal Model: Female C57BL/6N mice (8 weeks old)
Dosage: 1, 3, and 10 mg/kg
Administration: i.g., single dose
Result: Reduced PLC to 24.4 % of baseline at 4 h post administration, outperforming Fingolimod (36.3 %).
Promoted a rapid recovery of PLCs to 70.8 % of baseline within 28 hours, in contrast to Fingolimod (MS-N91571), which causes prolonged lymphopenia.
Produced a rapid reduction in lymphocyte counts to approximately 40 % of baseline at 3 h post administration and achieved maximal suppression at the 3 and 10 mg/kg doses by 6 h post administration, while triggering an early rebound in the 1 mg/kg group by the same time, suggesting the onset of recovery.
Elicited a stronger pharmacodynamic response at 3 and 10 mg/kg, and permitted full lymphocyte recovery in all groups within 24 hours.

化学信息

分子量 406.43
分子式 C23H22N2O5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础